dasatinib, Sprycel

Pharmacy Author:
Medical and Pharmacy Editor:

GENERIC NAME: dasatinib

BRAND NAME: Sprycel

DRUG CLASS AND MECHANISM: Dasatinib is an oral medication used for treating chronic myeloid leukemia and acute lymphoblastic leukemia. It is classified as a kinase inhibitor. Kinase inhibitors include Erlotinib (Tarceva), gefitinib (Iressa), imatinib (Gleevec), nilotinib (Tasigna), pazopanib (Votrient), sunitinib (Sutent), and vandetanib (Caprelsa). Kinase inhibitors prevent the growth of tumors by reducing the action of proteins that control cell division, growth, and survival. These proteins are usually present in larger quantities or are more active in cancer cells. By reducing the activity of these proteins, growth and survival of cancer cells are reduced. The FDA approved dasatinib in June 2006.

PRESCRIPTION: Yes

GENERIC AVAILABLE: No

PREPARATIONS: Tablets: 20, 50, 70, 80, 100, and 140 mg

STORAGE: Dasatinib should be stored at room temperature between 15-30 C (59-86 F).

PRESCRIBED FOR: Dasatinib is used for the treatment of newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML); treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib; and treatment of Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.




Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index